论文部分内容阅读
选取30例新诊断的严重(HbA1c>9%)T2DM患者,和30例经两种或两种以上OADs治疗后血糖不达标(HbA1c>7%)的T2DM患者为研究对象,应用双时相门冬胰岛素30每日二次或三次注射强化治疗,观察空腹血糖、餐后2h血糖、胰岛素用量及低血糖发生次数等指标的差异。结果:门冬胰岛素30强化控糖后两组性别、年龄、BMI、HbA1c、低血糖发生次数差异无统计学意义(P>0.05),(表1);初发T2DM组强化治疗血糖达标时间及胰岛素用量明显低于已使用口服降糖药但血糖不达标的T2DM组,差异有统计学意义(P<0.05)。(表2)。结论:预混胰岛素可作为胰岛素起始治疗方案,初发的T2DM尽早启动胰岛素治疗能够尽快纠正高血糖毒性,保护胰岛β细胞功能。
Thirty patients with newly diagnosed T2DM (HbA1c> 9%) and 30 T2DM patients (HbA1c> 7%) with two or more OADs after treatment were enrolled in this study. Insulin 30 twice daily or three times daily intensive treatment, observed fasting blood glucose, 2h postprandial blood glucose, insulin dosage and the frequency of hypoglycemia and other indicators of difference. Results: There was no significant difference in sex, age, BMI, HbA1c and incidence of hypoglycemia between aspartic insulin 30 and control group (P> 0.05) (Table 1) The amount of insulin was significantly lower than that of oral glucose-lowering drugs but did not meet the blood glucose T2DM group, the difference was statistically significant (P <0.05). (Table 2). CONCLUSION: Premixed insulin can be used as the initial treatment for insulin. Insulin treatment as soon as possible in T2DM can correct hyperglycemic toxicity and protect pancreatic β-cell function as soon as possible.